Hemic and Lymphatic Diseases

593 trials 238 recruiting

Filter these 593 trials by phase, country and sponsor.

Open in Search →

A Phase 2/3 Study in Adult and Pediatric Participants with SCD Suspended

2023-508766-14-00 Sickle Cell Disease 10
CD8 PET imaging study before and after CAR T-cell therapy Ended

2025-520560-18-00 Large B-cell lymphoma 10 2026-05-22
PD-L1 PET imaging during CAR T-cell therapy Ended

2024-518422-32-01 (Diffuse) Large B-cell Lymphoma 9 2026-05-20
A Study to Learn How Different Amounts of the Study Medicine Called PF-07940369 are Tolerated and Act in the Body in Healthy Adults Ended

2025-520558-12-00 Clonal hematopoiesis 3 2025-07-09
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents with Sickle Cell Disease during Vaso-Occlusive Crisis Ended

2024-513440-29-00 Sickle cell disease vaso-occlusive crisis 10 2025-06-25
A Study to Learn More About an Investigational Medicine called HDP-102 in Patients with Relapsed/Refractory B-cell Blood Cancers. Ended

2023-508759-38-00 Relapsed/Refractory B-cell Malignancies 1 2025-06-04
A Phase 1, Open-Label, 2-Period, 2-Formulation, Within-Subject Crossover Comparative Pharmacokinetic, Pharmacodynamic, and Safety Study of 1… Ended

2025-521615-39-00 not applicable (submitted trial is a pharmacokinetic an 3 2025-06-04
Phase 1 Safety and Tolerability Study of REGN9533 in Healthy Adults. Ended

2024-515285-14-00 Healthy Volunteers 1 2025-03-04
BATOLISA Ended

2024-513529-21-00 Lipedema 6 2025-01-24
With Ponatinib on the track for treatment-free-remission in chronic myeloid leukemia Ended

2024-518971-76-00 chronic myeloid leukemia in chronic phase 4 2024-12-21
KONFIDENT-KID Ended

2023-507591-44-00 Hereditary Angioedema Type I or II 5 2024-10-24
Venetoclax after TKI to target persisting stem cells in CML Ended

2024-516214-38-00 Chronic Myeloid Leukemia 4 2024-10-15
Safety of TEG001 in patients with r/r AML/high-risk MDS or r/r MM Ended

2024-517381-42-00 Acute Myeloid Leukemia (AML) 1 2024-10-14
A trial to learn if AZD9829 is safe and works alone and in combination with other treatments for participants with certain blood cancers. Ended

2023-506997-11-00 CD123-Positive Hematological Malignancies: Module 1 foc 1 2024-10-09
A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally In… Ended

2023-508603-21-00 Venous Thromboembolism 4 2024-09-20
A Phase I/IIa Study of ODX (OsteoDex) in Multiple Myeloma Ended

2024-516969-36-00 Multiple Myeloma 9 2024-09-16
A research study to evaluate the effects of single doses of NNC0614-0001 in healthy adult volunteers, and participants with hereditary haemo… Ended

2023-504574-38-00 Hereditary haemochromatosis (HH) type 1 3 2024-09-06
A Study to Learn How Different Amounts of the Study Medicine Called PF-07940369 are Tolerated and Act in the Body in Healthy Adults. Ended

2024-513467-47-00 clonal hematopoiesis 1 2024-08-08
Study to assess the safety, pharmacokinetics and efficacy of HMPL-523 in patients with Immune Thrombocytopenia Ended

2023-508819-23-00 Primary immune thrombocytopenia (ITP) 3 2024-07-24
A trial to learn how well REGN7508 works for preventing blood clots after a knee replacement in adult participants Ended

2023-508602-14-00 Thromboembolic disease 4 2024-06-27
A safety study of PF-08046045/SGN-35T in adults with advanced cancers Ended

2022-502390-41-00 Enteropathy-Associated T-Cell Lymphoma 1 2024-06-20
Long-term Safety and Efficacy Study of Fitusiran in Patients with Hemophilia A or B, with or without Inhibitory Antibodies to Factor VIII or… Ended

2023-508884-59-00 Hemophilia A or Hemophilia B 5 2024-06-03
Safety, pharmacokinetics, and preliminary efficacy of BYON4413 in acute myeloid leukemia and myelodysplastic neoplasms. Ended

2023-507781-13-00 Patients with relapsed/refractory acute myeloid leukemi 1 2024-05-24
A study to learn how safe and tolerable odronextamab and cemiplimab are in adult patients with B-cell malignancies Ended

2023-508209-25-00 B-Cell Non-Hodgkin’s Lymphoma (B-NHL) 1 2024-04-19